METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Clinical trials for METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Custom-Made cancer vaccine shows promise in advanced pancreatic and colorectal cancers
⭐️ VACCINE ⭐️ Recruiting nowThis early-stage trial is testing a personalized peptide vaccine made from a patient's own tumor cells and blood. The goal is to see if it's safe and feasible for people with advanced pancreatic or colorectal cancer that has spread. The vaccine is designed to help the immune syst…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: ⭐️ VACCINE ⭐️
Last updated May 16, 2026 22:26 UTC
-
New combo aims to tackle tough pancreatic cancer and prevent clots
Disease control Recruiting nowThis study tests a new drug called pegcetacoplan added to standard chemotherapy for people with metastatic pancreatic cancer. The goal is to see if the combination is safe and helps control the cancer longer. It also looks at whether pegcetacoplan can prevent dangerous blood clot…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated May 16, 2026 22:33 UTC
-
New hope for pancreatic cancer: Immune-Reprogramming drug trial launches
Disease control Recruiting nowThis study tests a new drug called ONT01 combined with standard chemotherapy for people with advanced pancreatic cancer that has worsened after initial treatment. The goal is to see if ONT01 can reprogram immune cells in the tumor to make the cancer more responsive to treatment. …
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated May 16, 2026 22:27 UTC
-
New hope for pancreatic cancer: drug combo trial launches
Disease control Recruiting nowThis early-phase trial tests whether adding an experimental MK2 inhibitor (zunsemetinib) to standard chemotherapy (mFOLFIRINOX) can better control metastatic pancreatic cancer. About 51 adults who have not had prior treatment for advanced disease will participate. The main goal i…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated May 16, 2026 22:27 UTC
-
New drug cocktails take on Hard-to-Treat gut cancers
Disease control Recruiting nowThis study is testing several new experimental drugs (RAS(ON) inhibitors) combined with standard chemotherapy or other targeted therapies for people with advanced colorectal or pancreatic cancer. The goal is to see if these combinations are safe and can shrink tumors. About 1,130…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated May 16, 2026 22:27 UTC
-
Promising new drug combo takes on deadly pancreatic cancer in major trial
Disease control Recruiting nowThis study tests whether a new drug combination (TQB2868 injection plus anlotinib capsules) with chemotherapy can help people with metastatic pancreatic cancer live longer compared to standard chemotherapy alone. About 566 adults aged 18-75 with stage IV pancreatic cancer will ta…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
Stem cell combo trial aims to outsmart Drug-Resistant cancers
Disease control Recruiting nowThis early-phase study tests a new treatment for people with metastatic pancreatic or breast cancer that has stopped responding to standard therapies. The treatment combines two chemotherapy drugs with high-dose vitamins and a stem cell transplant to help the body recover. The ma…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: General Oncology, Inc. • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
New pill takes on hard-to-treat KRAS cancers in first human trial
Disease control Recruiting nowThis early-phase study tests a new drug called BBO-11818 in adults with advanced lung, pancreatic, or colorectal cancers that have a KRAS mutation. The main goals are to check safety and find the best dose, while also seeing if the drug can shrink tumors. About 387 participants w…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) • Aim: Disease control
Last updated May 07, 2026 18:41 UTC
-
New drug cocktail takes on tough pancreatic cancer
Disease control Recruiting nowThis early-stage trial tests a new targeted drug (CA-4948) added to standard chemotherapy for people with pancreatic cancer that has spread or can't be removed. The goal is to find the safest dose and see if the combination can shrink tumors or slow the disease. About 43 adults w…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 07, 2026 18:39 UTC
-
New MRI scan could predict pancreatic cancer treatment success
Diagnosis Recruiting nowThis study tests a new type of MRI scan that uses a special contrast agent (hyperpolarized carbon-13 pyruvate) to see how pancreatic tumors process nutrients. The goal is to predict whether treatment is working earlier than standard scans. The study involves 70 adults with advanc…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Sponsor: University of California, San Francisco • Aim: Diagnosis
Last updated May 14, 2026 12:01 UTC
-
New drug aims to fight deadly wasting in pancreatic cancer patients
Symptom relief Recruiting nowThis study tests if adding ponsegromab to standard chemotherapy can help adults with advanced pancreatic cancer who are losing weight and have poor appetite (cachexia). About 982 participants will receive either ponsegromab or a placebo alongside their first chemo treatment. The …
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: Pfizer • Aim: Symptom relief
Last updated May 14, 2026 12:04 UTC
-
New drug OMO-103 studied in pancreatic cancer patients to reveal tumor changes
Knowledge-focused Recruiting nowThis early phase 1 trial is studying how the drug OMO-103 affects pancreatic cancer cells in 12 patients with advanced or metastatic disease. The main goal is to see if the drug causes measurable changes in the tumor's biology by comparing tissue samples taken before and after tr…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: EARLY_PHASE1 • Sponsor: OHSU Knight Cancer Institute • Aim: Knowledge-focused
Last updated May 16, 2026 22:29 UTC
-
New study peeks inside pancreatic tumors to find better drug targets
Knowledge-focused Recruiting nowThis study is for people with pancreatic cancer that can be removed by surgery or has spread. Researchers will give one of several drugs (cobimetinib, olaparib, onvansertib, azenosertib, AZD5305, or tremelimumab) for a short time before surgery or biopsy. By comparing tumor sampl…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: EARLY_PHASE1 • Sponsor: OHSU Knight Cancer Institute • Aim: Knowledge-focused
Last updated May 16, 2026 22:27 UTC
-
Blood test may speed up chemo decisions for pancreatic cancer patients
Knowledge-focused Recruiting nowThis study looks at whether a simple blood test (ctDNA) can tell doctors early on if chemotherapy is shrinking tumors in people with metastatic pancreatic cancer. Currently, doctors wait about 8 weeks for a scan to check, but this test might give answers in just 4 weeks. About 50…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: University of Miami • Aim: Knowledge-focused
Last updated May 13, 2026 15:58 UTC